Bathi resik saben saham (EPS TTM): Elevai Skincare (ELAB)

Amidst fierce competition in the biotech cosmetics market, Elevai Labs Inc. (ELAB) faces pressure from global luxury behemoths. Net earnings per share over the last four quarters reflect current yield dynamics, where -645.33 serves as the current parameter value. Moderate cyclicality in demand for premium skincare is complemented by streamlined exosome supply chains within the US, ensuring stable product distribution.

ELAB Bathi saben saham sajrone 12 wulan pungkasan Elevai Corp (21.02.2024 - 15.11.2026)

Elevai Skincare - rincian analitis lan metrik utama (ELAB)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega elevaiskincare.com|ELAB - Prakiraan konsensus analis

- indikator kapitalisasi bursa perusahaan:

Kapitalisasi pasar Elevai Labs|ELAB - Rega Tumbas Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Elevai Labs|ELAB - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku elevaiskincare.com|ELAB - Aset Perusahaan

- indikator beban kredit lan likuiditas emiten:

- data bathi lan kelipatan valuasi:

ELAB - Asil keuangan resik|Bathi mangsa ngarep Elevai Labs Inc.|ELAB - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Elevai Skincare|ELAB - Rasio rega marang bathi tumrap wutah|Pangali EV/EBITDA Elevai Labs Inc|ELAB - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Elevai Labs|ELAB - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan elevaiskincare.com|ELAB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Elevai Labs Inc.

- informasi babagan volume dodolan lan pendapatan:

ELAB - Pendapatan dodolan perusahaan|Prakiraan volume dodolan Elevai Labs Inc|ELAB - Koefisien rega marang pendapatan|Rasio rega marang prakiraan pendapatan Elevai Labs|ELAB - Wutah dodolan YoY sajrone 12 wulan kepungkur

Analisis dhasar perusahaan:Elevai Labs - ELAB

Investors must evaluate the competitiveness of Elevai Labs Inc. (ELAB) within the aesthetic medicine niche. This indicator measures net income allocated per share annually, excluding the impact of total issuance volume. By analyzing the company's EPS TTM trend, one can determine the monetization efficiency of its exosome formulations. Growth in this metric confirms cosmetologist loyalty and the successful scaling of online channels. A steady increase in this figure signals the long-term sustainability of the business model.

Analisis pesaing Elevai Labs Inc.